Literature DB >> 3523240

Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis.

V L Yu, A Goetz, M Wagener, P B Smith, J D Rihs, J Hanchett, J J Zuravleff.   

Abstract

We conducted a five-year prospective controlled study of prophylaxis of Staphylococcus aureus nasal carriage and infection among patients in a hemodialysis unit. Carriers tended to have chronic colonization with a single phage type. S. aureus infections occurred significantly more frequently in carriers than in noncarriers and, in 93 percent of the infected carriers, were caused by the same phage type as that carried in the nares. Neither intravenous vancomycin nor topical bacitracin was found to be efficacious in eradicating nasal carriage. However, oral rifampin given for five days decreased S. aureus carriage over a one-month follow-up period, but within three months colonization of the nares recurred in most carriers, often with an S. aureus of the original phage type. Carriers were then randomly assigned to receive either rifampin or no prophylaxis. Rifampin was readministered at three-month intervals if culture of the anterior nares yielded S. aureus. Infections with S. aureus occurred significantly more frequently in carriers given no prophylaxis than in those given a full course of rifampin. S. aureus resistant to rifampin was isolated from the anterior nares of four patients, but these isolates were not implicated in any infections. The incidence of infection at the dialysis access site, skin, and soft tissue of patients on hemodialysis can be decreased by interventions directed at nasal carriage of S. aureus.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3523240     DOI: 10.1056/NEJM198607103150204

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  81 in total

Review 1.  Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks.

Authors:  J Kluytmans; A van Belkum; H Verbrugh
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Staphylococcus aureus nasal carriage as a marker for subsequent staphylococcal infections in intensive care unit patients.

Authors:  X Corbella; M A Domínguez; M Pujol; J Ayats; M Sendra; R Pallares; J Ariza; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

Review 3.  Antimicrobial resistance: the example of Staphylococcus aureus.

Authors:  Franklin D Lowy
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

4.  Selective staphylococcal broth.

Authors:  R L Sautter; L W Wells
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

5.  Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.

Authors:  Clayton Harro; Robert Betts; Walter Orenstein; Eun-Jeong Kwak; Howard E Greenberg; Matthew T Onorato; Jon Hartzel; Joy Lipka; Mark J DiNubile; Nicholas Kartsonis
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

Review 6.  Measuring quality of life in clinical trials: a taxonomy and review.

Authors:  G H Guyatt; S J Veldhuyzen Van Zanten; D H Feeny; D L Patrick
Journal:  CMAJ       Date:  1989-06-15       Impact factor: 8.262

7.  c-di-GMP (3'-5'-cyclic diguanylic acid) inhibits Staphylococcus aureus cell-cell interactions and biofilm formation.

Authors:  David K R Karaolis; Mohammed H Rashid; Rajanna Chythanya; Wensheng Luo; Mamoru Hyodo; Yoshihiro Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

8.  Clinical Risk Factors for Infective Endocarditis in Staphylococcus aureus Bacteremia.

Authors:  Vincent Bryan D Salvador; Bikash Chapagain; Astha Joshi; Debra J Brennessel
Journal:  Tex Heart Inst J       Date:  2017-02-01

Review 9.  Antibacterial resistance.

Authors:  Jocelyn Y Ang; Elias Ezike; Basim I Asmar
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

10.  A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia.

Authors:  John M Boyce; Olivia-Fabiola Pop; Odaliz Abreu-Lanfranco; Whitney Y Hung; Ann Fisher; Afshin Karjoo; Benjamin Thompson; Zenon Protopapas
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.